摘要
To the Editor： I congratulate Wang et al1 in reporting further evidence for the role of matrix metalloproteinase-9 （MMP9）as a biomarker in acute coronary syndrome （ACS）. In this study, the Authors examined the levels of MMP9 and C-reactive protein （CRP） in patients with a clinical diagnosis of unstable angina pectoris who subsequently underwent coronary angiography to evaluate the presence of coronary artery disease.
To the Editor： I congratulate Wang et al1 in reporting further evidence for the role of matrix metalloproteinase-9 （MMP9）as a biomarker in acute coronary syndrome （ACS）. In this study, the Authors examined the levels of MMP9 and C-reactive protein （CRP） in patients with a clinical diagnosis of unstable angina pectoris who subsequently underwent coronary angiography to evaluate the presence of coronary artery disease.
